Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Shares of Novavax Inc. NVAX slid 2.28% to $6.85 Wednesday, on what proved to be an all-around mixed trading session for the ...

In the most recent trading session, Novavax (NVAX) closed at $6.85, indicating a -2.28% shift from the previous trading day.

Novavax, Inc. (NVAX) on Thursday announced preclinical data demonstrating that the company’s H5N1 bird flu vaccine candidate ...

Novavax reports strong immune responses from H5N1 avian flu vaccine candidate, showing promise in single and two-dose ...

Novavax, Inc. (Nasdaq: NVAX) today announced preclinical data demonstrating that Novavax's H5N1 avian pandemic influenza ...

Novavax, sold under the brand name Nuvaxovid, is a protein-based COVID-19 vaccine — the same technology used to develop many other common vaccines, including those for influenza and shingles.

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

Novavax stock has plummeted from $290 a share in February 2021 to around $50 recently. The FDA finally appears poised to authorize the company's vaccine, however.

Why Novavax’s vaccine was authorized 2 years into the pandemic Novavax CEO Stanley Erck discusses his company’s COVID-19 vaccine, which was authorized by the FDA this week.

Topline Shares for Novavax swelled by more than 130% Friday morning, after the biotech firm announced a $1.4 billion deal with Sanofi to commercialize its Covid vaccine and develop a new ...

And the Novavax Covid-19 vaccine that just got emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) is certainly new. It’s new in that it’s not completely new.